A new report from the Concerned Women for America Legislative Action Committee reveals that Planned Parenthood dramatically expanded its cross-sex hormone business in 2025, with a 40% surge in so-called “gender-affirming” drug sales at 14 of its largest affiliates — even as public opposition grows and multiple countries move to ban such interventions for minors.
The data is striking. Planned Parenthood Great Northwest, Hawaii, Alaska, Indiana, and Kentucky reported 24,295 gender-related services in 2025, up from 13,432 the prior year. Planned Parenthood of Greater Ohio saw transgender-related visits climb from 6,206 to 8,644. The Pasadena affiliate jumped from 1,544 to 2,346. A separate 2025 study identified Planned Parenthood as the nation’s leading provider of such interventions, with more than 120,000 people receiving gender drugs in recent years.
While some affiliates restrict these drugs to adults 18 and older, affiliates operating in California and Maryland dispense cross-sex hormones to minors as young as 16 and 17 with parental consent. Known side effects of these interventions include infertility, heart complications, metabolic disorders, and documented rates of long-term regret. Planned Parenthood’s own annual report omitted any detailed breakdown of transgender services, folding them under a generic “other procedures” category — in the same period the organization performed a record 434,450 abortions.
Planned Parenthood is not a healthcare organization. It is a revenue-maximizing enterprise that has identified gender confusion in young people as its next growth market, and it is scaling up accordingly — even as Sweden, Finland, England, and multiple U.S. states move to restrict or ban these interventions for children. The fact that Planned Parenthood buried these numbers in its own annual report tells you exactly how confident its leadership is that the public would approve.
Discussion about this post